Tin tức & Cập nhật
Xem bài viết Nội tiết
Xem
SGLT-2i lowers autoimmune rheumatic disease risk in T2D
The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, results in a reduced risk of autoimmune rheumatic disease among adults with type 2 diabetes (T2D), reports a recent study.
SGLT-2i lowers autoimmune rheumatic disease risk in T2D
04 Nov 2025
Empagliflozin 25 mg confers greater kidney protection than SGLT2i 10 mg in T2D
In patients with type 2 diabetes (T2D), empagliflozin 25 mg daily offers greater kidney protection than its 10 mg daily dose or dapagliflozin 10 mg daily, a retrospective cohort study in Hong Kong has shown.
Empagliflozin 25 mg confers greater kidney protection than SGLT2i 10 mg in T2D
03 Nov 2025
Free school meals tied to improved child health
A US cohort study of schools matched to child and adolescent patient medical records from a network of community health organizations found an association between school participation in the Community Eligibility Provision (CEP) programme and a net reduction in blood pressure (BP) outcomes.
Free school meals tied to improved child health
30 Oct 2025
Metformin helps reduce ADT-related complications in prostate cancer patients
Metformin seems inadequate in reducing the risk of metabolic syndrome (MS) in patients with prostate cancer receiving androgen deprivation therapy (ADT), results of the PRIME study have shown.